Bulk Pharmaceutical API Sources for TADALAFIL

Bulk Pharmaceutical API Sources for TADALAFIL

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-002-885-864
Amadis Chemical		A23556
AKos Consulting & Solutions		AKOS015892559

Tadalafil API Bulk Sources Overview

Last updated: February 14, 2026

Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, is primarily used for erectile dysfunction and pulmonary hypertension. Its manufacturing involves sourcing high-purity active pharmaceutical ingredients (APIs) from multiple global suppliers.

Major API Manufacturers and Suppliers

Supplier Name	Location	GMP Certification	Capacity (kg/year)	API Quality Standards	Notes
Teva Pharmaceutical Industries Ltd.	Israel	Yes	10,000+	USP, EP, ICH Q7	One of the earliest producers with large-scale capacity
Natco Pharma Ltd.	India	Yes	3,000+	USP, EP	Known for high-quality generics production
Sun Pharmaceuticals	India	Yes	4,500+	USP, EP, ISO	Significant global API supplier
Mylan/NAS (now part of Viatris)	India, USA	Yes	2,500+	USP, EP	Extensive API production infrastructure
Jiangsu Hengrui Medicine Co. Ltd.	China	Yes	2,000+	USP, EP	Large Chinese API manufacturer

Regional API Production Trends

• India: Dominates global API supply for tadalafil, accounting for over 50% of available API capacity. Companies like Natco, Sun Pharma, and Cipla hold significant manufacturing pipelines, driven by lower production costs and robust API regulatory infrastructure.

• China: Increasing presence with large-scale API manufacturing facilities; key players include Jiangsu Hengrui and Sino Biopharmaceutical. Chinese API manufacturers are expanding capacity, aiming to meet growing worldwide demand.

• Israel and USA: Smaller but high-quality API production bases with focus on compliance and regulatory standards, especially for markets with strict quality controls.

API Quality and Regulatory Compliance

• Most suppliers adhere to USP, EP, and ICH Q7 standards; these certifications ensure APIs meet safety, quality, and stability benchmarks.
• GMP certification is a mandatory requirement for bulk API manufacturers supplying to regulated markets, ensuring manufacturing quality control.

Supply Chain Considerations

• Capacity: Capacity varies widely from 2,000 kg to over 10,000 kg annually; supply chain flexibility depends on supplier capacity and demand fluctuations.
• Regulatory Status: Suppliers with established GMP and regulatory approvals are preferred for global commercial supply.
• Pricing: Cost differences primarily depend on regional manufacturing costs, scale, and certification standards.

Key Competitive Factors

• Manufacturing scale and capacity
• Compliance with international standards
• Lead times and supply reliability
• Cost competitiveness

Emerging API Sources

• Some emerging manufacturers in Southeast Asia and Eastern Europe are expanding API production, potentially influencing pricing and availability in the next 2-3 years.

Conclusion

The global tadalafil API market is driven by manufacturing capacity in India and China, with high-quality production from Israel and the USA. Leading suppliers meet regulatory standards specified by US, European, and international authorities, ensuring consistent supply for pharmaceutical companies.

---

Key Takeaways

• India and China dominate tadalafil API supply, providing over 90% of global capacity.
• Quality standards like USP, EP, and ICH Q7 are essential for regulatory approval.
• Capacity varies significantly, affecting supply reliability and pricing.
• Multiple suppliers maintain GMP certification to serve regulated markets.
• Emerging manufacturers could influence market dynamics through capacity expansion.

---

FAQs

1. What are the primary regions producing tadalafil API?
India and China lead, with India providing over half of global capacity; Israel and the USA offer high-quality sources with regulatory approvals.

2. How do quality standards impact API sourcing?
GMP compliance and certifications like USP, EP, ensure API quality meets regulatory expectations, critical for market approval.

3. What factors influence tadalafil API pricing?
Supplier capacity, region, quality compliance, and supply chain logistics are key determinants.

4. Are there regulatory risks with global API sources?
Yes, suppliers lacking GMP certification or approvals pose risks, especially for regulated markets, emphasizing the importance of supplier verification.

5. How might emerging suppliers affect the tadalafil API market?
They could offer competitive prices and increase supply capacity, potentially impacting pricing and supply stability in 2-3 years.

---

Sources

1. Teva Pharmaceuticals Annual Report 2022.
2. Natco Pharma Limited Annual Report 2022.
3. Sun Pharmaceutical Industries Ltd. Annual Report 2022.
4. Viatris (Mylan/NAS) API Manufacturing Capabilities.
5. Jiangsu Hengrui Medicine Co. Ltd. Corporate Data.